Inventor · disambiguated record
Jens Buchardt
Also filed as: BUCHARDT JENS
9 granted patents·15 pending applications·19 citations·filing 1999–2020
84Inventor score
Files withNOVO NORDISK AS9NOVO NORDISK HEALTHCARE AG7BEHRENS CARSTEN2BUCHARDT JENS2ANDERSEN METTE DAHL1
Top patents by PatentIndex Score
24 records- 0185US8841249B2Growth hormones with prolonged in-vivo efficacyJOHANSEN NILS LANGELAND·Filed 2010·Granted Sep 23, 2014·9 cites·4 claims
- 0280US9018166B2Conjugated FVIII variantsBEHRENS CARSTEN·Filed 2011·Granted Apr 28, 2015·2 cites·9 claims
- 0375US2020102568A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 0473US9737612B2Antagonistic DR3 ligandsANDERSEN METTE DAHL·Filed 2012·Granted Aug 22, 2017·3 cites·17 claims
- 0570US9695226B2Growth hormones with prolonged in-vivo efficacyBEHRENS CARSTEN·Filed 2011·Granted Jul 4, 2017·1 cites·14 claims
- 0665US8586532B2Method for selectively modifying a protein via transglutaminase catalyzed reactionBUCHARDT JENS·Filed 2008·Granted Nov 19, 2013·2 cites·20 claims
- 0765US2020306382A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2020·Application pending·0 cites
- 0863US2019203213A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 0960US2014329750A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2014·Application pending·0 cites
- 1059US9713644B2Antagonistic DR3 ligandsNOVO NORDISK AS·Filed 2014·Granted Jul 25, 2017·0 cites·27 claims
- 1158US2017239362A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2017·Application pending·0 cites
- 1257US8765130B2Antagonistic DR3 ligandsNOVO NORDISK AS·Filed 2013·Granted Jul 1, 2014·0 cites·23 claims
- 1357US2018221501A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2017·Application pending·0 cites
- 1456US2013040888A1Factor VIII Molecules With Reduced VWF BindingNOVO NORDISK AS·Filed 2011·Application pending·0 cites
- 1555US2017020992A1Factor VIII Molecules with Reduced VWF BindingNOVO NORDISK AS·Filed 2016·Application pending·0 cites
- 1653US2017305994A1Antagonistic DR3 LigandsNOVO NORDISK AS·Filed 2017·Application pending·0 cites
- 1752US2015376262A1Factor VIII Molecules With Reduced VWF BindingNOVO NORDISK AS·Filed 2015·Application pending·0 cites
- 1850US2016251409A1Targeted Delivery of Factor VIII Proteins to PlateletsNOVO NORDISK AS·Filed 2016·Application pending·0 cites
- 1947US2010009917A1Modulating Enzymatic Processes by Addition of Diolcontaining SubstancesNOVO NORDISK HEALTHCARE AG·Filed 2008·Application pending·0 cites
- 2043US2013012684A1Purification MethodNOVO NORDISK AS·Filed 2011·Application pending·0 cites
- 2141US2012093840A1Targeted delivery of factor viii proteins to plateletsOESTERGAARD HENRIK·Filed 2010·Application pending·0 cites
- 2239US2016024487A1Thrombin sensitive coagulation factor x moleculesNOVO NORDISK AS·Filed 2014·Application pending·0 cites
- 2333US9234192B2Conjugated proteinsBUCHARDT JENS·Filed 2011·Granted Jan 12, 2016·0 cites·14 claims
- 2428US7064179B1Peg-based macromonomers, chemically inert polymers prepared therefrom and the use of these polymers for organic synthesis and enzyme reactionsCARLSBERG AS·Filed 1999·Granted Jun 20, 2006·2 cites·17 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →